Literature DB >> 7963410

Terbinafine-associated hepatic injury.

J W van 't Wout1, W A Herrmann, R A de Vries, B H Stricker.   

Abstract

We describe two cases of terbinafine-associated hepatic injury, in which a mixed cholestatic-hepatocellular type of hepatitis was present. In both cases extrahepatic cholestasis and viral hepatitis were excluded and involvement of other drugs was unlikely. In the first patient all abnormalities have disappeared, but in the second patient alkaline phosphatase, aminotransferase and gamma-glutamyl transferase levels have remained elevated (follow up 3 months after cessation of treatment with terbinafine). Most likely, the terbinafine-associated hepatic injury in these patients was caused by an idiosyncratic rather than a direct hepatotoxic reaction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7963410     DOI: 10.1016/s0168-8278(94)80146-0

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  7 in total

1.  A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs.

Authors:  L A García Rodríguez; A Duque; J Castellsague; S Pérez-Gutthann; B H Stricker
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

Review 2.  Systematic review of severe acute liver injury caused by terbinafine.

Authors:  Jun Yan; Xiaolin Wang; Shengli Chen
Journal:  Int J Clin Pharm       Date:  2014-07-02

Review 3.  Terbinafine. An update of its use in superficial mycoses.

Authors:  K J McClellan; L R Wiseman; A Markham
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

4.  Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts.

Authors:  A Mallat; E S Zafrani; J M Metreau; D Dhumeaux
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

Review 5.  Terbinafine-induced hepatitis and pancytopenia.

Authors:  G Conjeevaram; V Vongthavaravat; R Sumner; R S Koff
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.487

6.  Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study.

Authors:  Shinichi Watanabe; Ichiro Tsubouchi; Akihiro Okubo
Journal:  J Dermatol       Date:  2018-08-29       Impact factor: 4.005

7.  Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality.

Authors:  Boni Elewski; Amir Tavakkol
Journal:  Ther Clin Risk Manag       Date:  2005-12       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.